| Primary Peritoneal Serous Adenocarcinoma studied in …STUDIED_INderived60 of 60show fewer |
|---|
| → studied in | NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 60 trials mapped (29 active) | — | — | Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04575935Phase 3 · recruiting Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07772869NA · recruiting Uterine Lavage to Detect Ovarian Cancer Risk · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ALIAS · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Papillary Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04034927Phase 2 · active not recruiting Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02068794Phase 1/Phase 2 · active not recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05415709early Phase 1 · active not recruiting Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03943173early Phase 1 · active not recruiting Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00488878recruiting Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05114421Phase 2 · active not recruiting Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients · condition mapped CURATED_BROADER · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101788Phase 2/Phase 3 · completed Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · condition mapped CURATED_BROADER · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04616534Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03586661Phase 1 · completed Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01116648Phase 1/Phase 2 · active not recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03587311Phase 2 · active not recruiting Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00951496Phase 3 · completed Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01167712Phase 3 · active not recruiting Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02659241early Phase 1 · active not recruiting Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04095364Phase 3 · active not recruiting Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04919629Phase 2 · recruiting APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00565851Phase 3 · active not recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02111941early Phase 1 · completed Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06639074Phase 2 · recruiting Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial · condition mapped CURATED_BROADER · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393751Phase 1/Phase 2 · withdrawn Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02713386Phase 1/Phase 2 · completed Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02756130Phase 1/Phase 2 · withdrawn Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03648489Phase 2 · completed Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02020707Phase 1 · completed Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02923739Phase 2 · terminated Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03641287NA · terminated The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05295589Phase 2 · withdrawn Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy · condition mapped CURATED_BROADER · 60 trials mapped (29 active) | — | — | Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02898207Phase 1 · completed Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01097746Phase 2 · completed First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03924245Phase 1 · terminated Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02316834early Phase 1 · completed Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00888615Phase 2 · completed Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00989651Phase 1 · completed Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02853318Phase 2 · completed Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00108745Phase 3 · unknown Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00551070Phase 2 · completed Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02283658Phase 2 · completed Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Papillary Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01504126early Phase 1 · completed Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00262847Phase 3 · completed Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01010126Phase 2 · completed Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer · condition mapped ALIAS · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Papillary Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00899093terminated YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00719303Phase 3 · unknown Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02627430Phase 1 · withdrawn Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00275028Phase 2 · completed AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00053235withdrawn Research Study in Patients With Advanced Ovarian Epithelial Cancer · condition mapped ALIAS · 60 trials mapped (29 active) | — | — | Primary Peritoneal Serous Papillary Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |